AUS
NZ
UK
CA
USA
IND
Highlights
- ANGLE PLC (AGL) has achieved a dual workflow for ctDNA and CTC DNA testing using the Illumina platform.
- The new method reveals DNA variants in circulating tumor cells that are not seen in fragmented cell-free DNA.
- Integration of artificial intelligence enhances data interpretation, supporting advancements in liquid biopsy technologies.
The biotechnology sector is known for rapid advancements in medical research, particularly in cancer diagnostics. Liquid biopsy techniques enable the non-invasive examination of blood samples to uncover genetic material from tumors. ANGLE PLC (LSE:AGL) has become a notable entity in this space by developing innovative methods that enhance the ability to capture and study circulating tumor cells (CTCs) alongside cell-free DNA (ctDNA). Such breakthroughs contribute to a deeper understanding of tumor genetics and provide critical insights for clinical research.
Innovative Dual DNA Workflow
A breakthrough has been achieved with a dual DNA workflow that simultaneously examines both ctDNA and CTC DNA on the Illumina sequencing platform. This approach was finalized over a period of several months and involved overcoming technical challenges to create an end-to-end solution. The system employs a specialist lung cancer DNA kit to process samples from a study involving a group of lung cancer patients. Remarkably, DNA variants were identified in circulating tumor cells for every patient in one subset, while these variants were not found in the ctDNA. In other patient groups undergoing treatment, a significant fraction of cases exhibited clinically relevant variants in CTC DNA that were absent from ctDNA. This finding underscores the importance of analyzing intact cells to obtain a comprehensive genetic profile of tumors.
Strategic Partnership with Illumina
The collaboration between ANGLE PLC and Illumina represents an important strategic alliance. Illumina, a leader in sequencing technologies, has recognized the breakthrough by dedicating an entire webinar at a major international cancer research conference to showcase the findings. The partnership facilitates a co-marketing initiative that leverages Illumina’s vast customer base and technological expertise, thereby expanding the reach of ANGLE’s innovations. This alliance is expected to strengthen the adoption of dual testing methodologies in clinical research and enhance the overall capabilities of liquid biopsies.
Integration of Artificial Intelligence
The new workflow incorporates artificial intelligence to process and interpret complex molecular data. AI systems have been employed to examine protein patterns on cells through image processing and to decode molecular signatures from fragmented ctDNA data. By ensuring that high-quality samples from intact cancer cells are utilized, AI-driven systems can derive more meaningful insights into tumor biology. This integration of advanced computing with robust sample preparation reinforces the importance of data quality in obtaining accurate results from liquid biopsy platforms.
Implications for Cancer Diagnostics
The advancements achieved by ANGLE PLC offer a new perspective on liquid biopsy methodologies. By capturing and analyzing circulating tumor cells, a more comprehensive view of tumor genetics is obtained compared to relying solely on cell-free DNA. The innovative combination of dual DNA workflows, strategic industry partnerships, and AI integration marks a significant step forward in refining cancer diagnostics and treatment planning within the biotechnology field.
